Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$29.22 -0.5%	$30.03	$24.48 ▼ $36.45	$4.84B	0.44	1.73 million shs	1.40 million shs
FOLD Amicus Therapeutics	$5.96 -5.2%	$6.07	$5.51 ▼ $12.65	$1.94B	0.51	3.25 million shs	5.16 million shs
LGND Ligand Pharmaceuticals	$139.10 +1.1%	$112.10	$90.29 ▼ $139.71	$2.65B	0.84	119,379 shs	347,058 shs
MNKD MannKind	$3.76 -3.6%	$4.02	$3.51 ▼ $7.63	$1.19B	0.96	2.43 million shs	2.31 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-0.48%	-3.50%	-0.38%	+8.01%	+18.73%
FOLD Amicus Therapeutics	-5.25%	-2.13%	+4.01%	-12.74%	-43.77%
LGND Ligand Pharmaceuticals	+1.11%	+14.30%	+21.34%	+32.51%	+37.63%
MNKD MannKind	-3.59%	-0.27%	-1.31%	-17.18%	-35.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.8283 of 5 stars	4.4	1.0	4.2	3.7	2.5	1.9
FOLD Amicus Therapeutics	4.1511 of 5 stars	3.4	1.0	4.3	3.3	0.0	1.9
LGND Ligand Pharmaceuticals	3.5262 of 5 stars	1.5	1.0	4.4	2.1	3.3	1.9
MNKD MannKind	2.6265 of 5 stars	3.6	0.0	0.0	2.2	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.83	Moderate Buy	$40.92	40.03% Upside
FOLD Amicus Therapeutics	2.80	Moderate Buy	$16.22	172.18% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$147.17	5.80% Upside
MNKD MannKind	3.25	Buy	$10.14	169.76% Upside

Current Analyst Ratings Breakdown

Latest MNKD, ALKS, LGND, and FOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	FOLD Amicus Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
7/16/2025	MNKD MannKind	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$9.00
7/15/2025	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$43.00
6/17/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$33.00 ➝ $42.00
5/28/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$45.00
5/13/2025	ALKS Alkermes	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/2/2025	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/2/2025	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$39.00 ➝ $40.00
5/2/2025	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$38.00 ➝ $41.00
5/2/2025	FOLD Amicus Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $22.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.56B	3.09	$2.64 per share	11.07	$9.05 per share	3.23
FOLD Amicus Therapeutics	$528.29M	3.47	N/A	N/A	$0.65 per share	9.17
LGND Ligand Pharmaceuticals	$167.13M	16.05	$1.62 per share	85.61	$43.95 per share	3.16
MNKD MannKind	$297.60M	3.84	$0.13 per share	28.10	($0.29) per share	-12.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.09	13.98	21.33	1.83	23.30%	27.52%	17.98%	7/29/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	13.86	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	37.49	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)
MNKD MannKind	$27.59M	$0.10	37.60	16.35	N/A	10.12%	-32.41%	10.85%	8/6/2025 (Estimated)

Latest MNKD, ALKS, LGND, and FOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FOLD Amicus Therapeutics	$0.01	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	MNKD MannKind	$0.04	N/A	N/A	N/A	$77.82 million	N/A
8/5/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	N/A	N/A	N/A	$43.87 million	N/A
7/29/2025	Q2 2025	ALKS Alkermes	$0.42	N/A	N/A	N/A	$343.20 million	N/A
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/8/2025	Q1 2025	MNKD MannKind	$0.03	$0.04	+$0.01	$0.04	$75.86 million	$78.35 million
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.33	2.92
FOLD Amicus Therapeutics	2.02	3.34	2.47
LGND Ligand Pharmaceuticals	N/A	5.27	5.02
MNKD MannKind	N/A	2.36	2.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
FOLD Amicus Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%
MNKD MannKind	49.55%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
FOLD Amicus Therapeutics	2.20%
LGND Ligand Pharmaceuticals	7.00%
MNKD MannKind	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	1,800	164.90 million	157.65 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable
MNKD MannKind	400	303.93 million	295.73 million	Optionable

MNKD, ALKS, LGND, and FOLD Headlines

Recent News About These Companies

MannKind (NASDAQ:MNKD) Upgraded at Wall Street Zen

35 minutes ago | marketbeat.com

MannKind Corporation (NASDAQ:MNKD) Director Steven B. Binder Sells 75,367 Shares

4 hours ago | marketbeat.com

Insider Selling: MannKind Corporation (NASDAQ:MNKD) Director Sells 75,367 Shares of Stock

July 18 at 9:36 AM | insidertrades.com

HC Wainwright Estimates MannKind's Q2 Earnings (NASDAQ:MNKD)

July 18 at 9:34 AM | marketbeat.com

MannKind's (MNKD) Buy Rating Reiterated at HC Wainwright

July 16 at 8:37 AM | marketbeat.com

Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT

July 11, 2025 | insidermonkey.com

MannKind (NASDAQ:MNKD) Hits New 52-Week Low - Here's Why

July 7, 2025 | marketbeat.com

MannKind (NASDAQ:MNKD) Hits New 1-Year Low - What's Next?

July 1, 2025 | marketbeat.com

MannKind (NASDAQ:MNKD) Rating Lowered to "Hold" at Wall Street Zen

June 27, 2025 | marketbeat.com

Health Rounds: Inhaled insulin as good as injection for children at mealtime

June 25, 2025 | reuters.com

MannKind (NASDAQ:MNKD) Stock Price Down 5.6% - What's Next?

June 25, 2025 | marketbeat.com

Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating

June 24, 2025 | insidermonkey.com

MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Buy" by Brokerages

June 24, 2025 | marketbeat.com

MannKind FY2026 EPS Forecast Decreased by Leerink Partnrs

June 19, 2025 | marketbeat.com

MannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical Data

June 16, 2025 | tipranks.com

Insider Selling: MannKind Co. (NASDAQ:MNKD) Director Sells 64,085 Shares of Stock

June 11, 2025 | insidertrades.com

Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD)

June 10, 2025 | gurufocus.com

MannKind’s Strategic Growth Potential and Market Positioning: A Buy Recommendation

June 10, 2025 | tipranks.com

MannKind Corp (MNKD) to Showcase Inhaled Insulin at ADA's 85th Scientific Sessions | MNKD stock news

June 9, 2025 | gurufocus.com

MannKind Corporation to Showcase Inhaled Insulin Innovations at ADA's 85th Scientific Sessions

June 9, 2025 | quiverquant.comQ

MannKind to present inhaled insulin study at ADA event

June 9, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD, ALKS, LGND, and FOLD Company Descriptions

Alkermes NASDAQ:ALKS

$29.22 -0.14 (-0.48%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$29.50 +0.28 (+0.96%)

As of 07/18/2025 04:32 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Amicus Therapeutics NASDAQ:FOLD

$5.96 -0.33 (-5.25%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.98 +0.02 (+0.40%)

As of 07/18/2025 07:34 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals NASDAQ:LGND

$139.10 +1.53 (+1.11%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$139.14 +0.04 (+0.03%)

As of 07/18/2025 07:37 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

MannKind NASDAQ:MNKD

$3.76 -0.14 (-3.59%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.80 +0.04 (+1.04%)

As of 07/18/2025 07:58 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time